¾üÊÂҽѧ¿ÆÑ§ÔºNature×Ó¿¯½ÒʾDNAÐÞ¸´Ð»úÖÆ
ÉúÎïͨ±¨µÀ À´×Ô¾üÊÂҽѧ¿ÆÑ§Ôº·ÅÉäÓë·øÉäҽѧÑо¿Ëù¡¢ÃÀ¹ú÷°ÂÕïËù(Mayo Clinic)¡¢»ªÊ¢¶Ù´óѧµÈ´¦µÄÑо¿ÈËԱ֤ʵ£¬Ï¸°ûÖÜÆÚÒÀÀµÐÔBRCA1¨CUHRF1¼¶Áª·´Ó¦µ÷¿ØÁËDNAË«Á´¶ÏÁÑÐÞ¸´ÐźÅͨ·µÄÑ¡Ôñ¡£ÕâÒ»Ñо¿·¢ÏÖ·¢²¼ÔÚ1ÔÂ5Èյġ¶×ÔȻͨѶ¡·£¨Nature Communications£©ÔÓÖ¾ÉÏ¡£
¾üÊÂҽѧ¿ÆÑ§Ôº·ÅÉäÓë·øÉäҽѧÑо¿Ëù±±¾©µ°°×ÖÊ×éÑо¿ÖÐÐĵÄÅỪ¶«£¨Huadong pei£©Ñо¿Ô±¼°Â¥ÕñÀ¥(Zhenkun Lou)½ÌÊÚÊÇÕâÆªÂÛÎĵĹ²Í¬Í¨Ñ¶×÷Õߣ¨ÑÓÉìÔĶÁ£º¾üÊÂҽѧ¿ÆÑ§ÔºCell×Ó¿¯½ÒʾDNAÐÞ¸´Ð»úÖÆ £©¡£
DNAË«Á´¶ÏÁÑ(DSBs)ÑÏÖØÎ£º¦ÁËϸ°û»îÁ¦ºÍ»ùÒò×éÎȶ¨ÐÔ¡£ÕýÈ·ÐÞ¸´È¾É«ÌåDSBs¶ÔÓÚά³Ö»ùÒò×éÎȶ¨ÐÔ£¬·ÀÖ¹Ö×Áö·¢ÉúÖÁ¹ØÖØÒª¡£ÔÚÕæºËϸ°ûÖУ¬·ÇͬԴĩ¶ËÁ¬½Ó(NHEJ)ºÍÍ¬Ô´ÖØ×é(HR)Êǽ鵼DSBsÐÞ¸´µÄÁ½¸ö¹Ø¼üÐźÅͨ·¡£Æô¶¯ÕâЩ¹ý³ÌÊܵ½ÑÏÃܵĵ÷¿Ø£¬Òì³£Ðźż¤»î»áµ¼Ö»ùÒò×é²»Îȶ¨¡£NHEJÊÇͨ¹ýÖØÐÂÁ¬½Ó¶ÏÁÑDNAÄ©¶ËÀ´ÐÞ¸´DSBs¡£Ã»ÓÐÀûÓÃͬԴģ°åÀ´Ö¸µ¼ÐÞ¸´£¬NHEJÓÐЧµ«ÈÝÒ׳ö´í¼°Í»±ä¡£HRÀûÓÃÁ˽ãÃÃȾɫµ¥ÌåÖеÄͬԴÐòÁÐÀ´×÷Ϊģ°å£¬Æô¶¯ÐÞ¸´ºÏ³É¼°»Ö¸´È¾É«ÌåÍêÕûÐÔ£¬±»ÊÓ×÷ÊÇÒ»ÖÖÎÞ´íÎóµÄDSBÐÞ¸´»úÖÆ¡£
ÔÚϸ°ûÖÜÆÚ¹ý³ÌÖÐHRºÍNHEJÖ®¼äµÄÑ¡ÔñÊܵ½ÑϸñµØµ÷¿Ø¡£NHEJÔÚÕû¸öϸ°ûÖÜÆÚ¹ý³ÌÖз¢»Ó¹¦ÄÜ£¬¶øHRÖ÷Òª·¢ÉúÓÚϸ°ûÖÜÆÚÖдæÔÚ½ãÃÃȾɫÌåµÄSºÍG2ÆÚ¡£ÔÚG1ÆÚ£¬ÓÉÓÚÎÞ·¨ÀûÓýãÃÃȾɫÌ壬ÇÒDNAÄ©¶ËÇгýÊܵ½ÒÖÖÆ£¬NHEJÊÇΨһµÄÑ¡Ôñ¡£ÔÚSÆÚϸ°ûÖУ¬DSBÄ©¶ËÇгý¿Éµ¼ÖÂÆô¶¯HR¡£Òò´Ë£¬ÐÞ¸´ÐźÅͨ·ѡÔñ´ÓNHEJÇл»ÖÁHR¡£53Bp1ºÍBRCA1ÔÚÕâÒ»¹ý³ÌÖз¢»ÓÏà·´µÄ×÷Ó᣽üÆÚµÄһЩÑо¿½Òʾ£¬ÔÚG1ÆÚϸ°ûÖÐ53Bp1¿Éͨ¹ýÕÐļÏÂÓÎЧӦÒò×ÓRIF1£¬×èÖ¹BRCA1 DSBλµãÖØ¶¨Î»£¬´Ù½øÁËNHEJ¡£
¿ÉÖØ¸´Ê¹ÓúIJĵÄÈ«ÐÂCountess II×Ô¶¯Ï¸°û¼ÆÊýÒÇ Ãâ·ÑÉêÇëDemo£¡
ÔÚG1ÆÚ£¬RIF1ͨ¹ýÓëÁ×Ëữ53Bp1»¥×÷¾Û¼¯ÔÚDSBλµã£¬×èÖ¹ÁË5¡äÄ©¶ËÇгý²¢´Ù½øÁËNHEJ¡£ÔÚȱ·¦RIF1µÄÇé¿öÏ£¬DSBs±»¹ý¶ÈÇгý£¬Ï¸°ûÏÔʾG1ÌØÒìÐÔµçÀë·øÉä¸ß¶ÈÃô¸ÐÐÔ¡£ÓëÖ®Ïà·´£¬ÔÚSÆÚϸ°ûÖУ¬RIF1ÒÔÒ»ÖÖBRCA1ÒÀÀµÐÔ·½Ê½´ÓDSBλµãÒÆ³ý£¬Õâ¶ÔÓÚÆô¶¯HRÖÁ¹ØÖØÒª¡£ÔÚÕâÖÖÇé¿öÏ£¬ÔÚSÆÚBRCA1ͨ¹ý´ÓDSBsλµã³ýÈ¥RIF1´Ù½øÁËHR¡£
E3·ºËØÁ¬½ÓøUHRF1ÊÇÒ»¸öÖØÒªµÄ±í¹ÛÒÅ´«µ÷¿ØÒò×Ó¡£Ò»Ð©Ñо¿½ÒÊ¾ÆÆ»µUHRF1¹¦Äܿɵ¼Ö¶ÔDNAËðÉ˸߶ÈÃô¸Ð£¬±íÃ÷UHRF1ÔÚά³Ö»ùÒò×éÎȶ¨ÐÔÖÐÆð¹Ø¼ü×÷Óᣵ«µ±Ç°¶ÔÓÚUHRF1ÔÚDNAÐÞ¸´Ñ¡ÔñÖеÄ×÷ÓÃÈÔ²»Çå³þ¡£
ÔÚÕâÆªÎÄÕÂÖУ¬Ñо¿ÈËԱ֤ʵUHRF1Ö±½Ó²ÎÓëÁËBRCA1ºÍ53Bp1Ö®¼äµÄ»¥×÷¡£»úÖÆÑо¿½Òʾ£¬ÔÚSÆÚBRCA1½«UHRF1ÕÐļµ½DSBs´¦£¬BRCA1µÄBRCT½á¹¹Óò¼°UHRF1Á×ËữSer674ÊÇÆä±ØÒªÌõ¼þ¡£Ëæºó£¬UHRF1½éµ¼RIF1 K63¶à¾Û·ºËØ»¯£¬µ¼ÖÂÁËRIF1Óë53Bp1ºÍDSBs·ÖÀ룬ÓÉ´Ë´Ù½øÆô¶¯ÁËHR¡£
ÕâЩ½á¹û±íÃ÷£¬UHRF1ÊÇDSBÐÞ¸´ÐźÅͨ·ѡÔñµÄÒ»¸ö¹Ø¼üµ÷¿ØÒò×Ó£¬Õâ¶ÀÁ¢ÓÚËüÔÚÒìȾɫÖÊÐγɺͱí¹ÛÒÅ´«µ÷¿ØÖÐËùÆðµÄ×÷Óá£
£¨ÉúÎïͨ£ººÎæÍ£©
ÉúÎïÍ¨ÍÆ¼öÔÎÄÕªÒª£º
A cell cycle-dependent BRCA1¨CUHRF1 cascade regulates DNA double-strand break repair pathway choice
BRCA1 is an important mediator of the DNA damage response, which promotes homologous recombination (HR) and antagonizes 53Bp1-dependent non-homologous end joining in S/G2 phase. But how this is achieved remains unclear. Here, we report that the E3 ubiquitin ligase UHRF1 (Ubiquitin-like, with pHD and RING finger domains 1) directly participates in the interplay between BRCA1 and 53Bp1. Mechanistically, UHRF1 is recruited to DNA double-strand breaks (DSBs) by BRCA1 in S phase, which requires the BRCT domain of BRCA1 and phosphorylated Ser674 of UHRF1. Subsequently, UHRF1 mediates K63-linked polyubiquitination of RIF1, and results in its dissociation from 53Bp1 and DSBs thereby facilitating HR initiation. Thus, UHRF1 is a key regulator of DSB repair choice, which is separate from its role in heterochromatin formation and epigenetic regulator.
×÷Õß¼ò½é£º
ÅỪ¶«
¾üÊÂҽѧ¿ÆÑ§Ôº·ÅÉäÓë·øÉäҽѧÑо¿ËùÑо¿Ô±,±±¾©µ°°×ÖÊ×éÑо¿ÖÐÐÄDNAËðÉËÐÞ¸´Ñо¿¿ÎÌâ×鳤¡¢²©Ê¿Éúµ¼Ê¦,¹ú¼Ò¡°ÇàÄê****¡±ÈëÑ¡Õß¼°¡°±±¾©ÊÐÇàÄ꺣¾ÛÈ˲żƻ®¡±×ÊÖú¶ÔÏó
Ñо¿·½Ïò£º
Ö÷ÒªÀûÓÃÉú»¯Óë·Ö×ÓÒÅ´«Ñ§¼¼Êõ£¬´ÓÊÂDNAËðÉËÐÞ¸´Ó¦´ðÓë»ùÒò×é²»Îȶ¨ÐÔ¼°Ö×Áö³ÉÒò·Ö×Ó»úÀíÑо¿¡£½üÄêÀ´ÓÖ¿ªÕ¹ÁËÖ×Áöϸ°û´úлµ÷¿ØÑо¿¡£ÒÔµÚÒ»×÷Õß»òÕßͨѶ×÷ÕßÔÚNature£¬Cancer Cell µÈÔÓÖ¾·¢±íÂÛÎÄ10ÓàÆª£¬ËûÒýÓâ300´Î¡£